physiological actions, including a glucose-dependent insulinotropic effect, inhibition of glucagon secretion, inhibition of both gastric emptying and food intake, and stimulation of -cell proliferation, etc. [3] [4] [5] [6] Therefore, GLP-1 has great therapeutic potential to treat diabetes type 2. However, the clinical application of native GLP-1 is limited by its very short half-life in vivo due principally to its rapid degradation by dipeptidyl peptidase IV (DPP IV) and/or renal clearance. 7) Accordingly, developing long-acting GLP-1 analogs to circumvent the rapid degradation and renal clearance of GLP-1 is of considerable interest. 8) Recent efforts have involved producing DPP IV-resistant GLP-1 analogs via amino acid substitution, 9, 10) hindering the renal clearance of GLP-1 by conjugating it to other molecules, 11, 12) and attenuating the degradation of GLP-1 in vivo using DPP IV inhibitors. 13, 14) Universally, conjugating peptides or smaller proteins of short half-life with certain carrier molecules, such as human serum albumin (HSA), and polyethylene glycol (PEG), significantly improved their pharmacokinetic properties. [15] [16] [17] Liraglutide and CJC-1131 are two GLP-1 analogs with chemical modifications, that can bind noncovalently or covalently to HSA in vivo and exhibited a half-life of more than 10 h above after administration. 18) In addition, Lee et al. studied the in vitro and in vivo activity of a PEGylated GLP-1 analog, and the results indicated that it had the bioactivity of native GLP-1, and that its in vivo half-life was significantly prolonged. 12) However, to date, studies of the expression and purification of GLP-1 fusion protein with similar bioactivity have been few.
Immunomagnetic separation (IMS), which utilizes magnetic microspheres (MMS) as the basis for separation, takes advantage of the selectivity of affinity chromatography with the high availability and efficiency of magnetic response, because MMS can be collected y To whom correspondence should be addressed. Tel/Fax: +86-22-23508371; E-mail: gangbai@nankai.edu.cn easily when a magnetic field is applied. 19, 20) When coupled with appropriate ligands such as antigens or antibodies, they provide an effective tool for achieving rapid, simple and specific target protein separation. 21, 22) In this study, we expressed the fusion protein of GLP-1/HSA utilizing the secretor type Pichia pastoris expression system and then evaluated the in vivo activity of GLP-1/HSA purified by IMS.
Materials and Methods
Reagents. Standard GLP-1 and HSA were from Sigma (St. Louis, MO). All restriction enzymes, Pfu DNA polymerase, and T4 DNA ligase were from Takara(Dalian, China). Geneticin (G418) was from Dingguo Biotechnology (Beijing, China). Mouse anti-GLP-1 (7-37) polyclonal antibody was from Phoenix (Beijing, China). Horseradish peroxidase (HRP) labeled goat antirabbit (and mouse) IgGs were purchased from TBD Bio. (Tianjin, China). The glucose kit was from Biosino Biotechnology and Science (Beijing, China). The other reagents used in this study were of analytical grade and are commercially available.
Strains and vectors. Pichia pastoris host strain GS115 (his4) and the eukaryotic expression vector pPIC9K were kindly provided by Professor Laijun Xing (College of Life Sciences, Nankai University, Tianjin, China). Recombinant vectors pMD18T/GLP-1 and pMD18T/ HSA were constructed in our laboratory.
Mice. Female Chinese Kunming (KM) mice (Academy of Military Medical Science, Beijing, China) were maintained on a 12 h light/dark cycle and allowed free access to standard rodent food and water, except where noted. The KM mice were used at 7 to 8 weeks old and acclimated to the animal facility for a minimum of 1 week before analysis.
Construction of expression vector and transformation of P. pastoris cells. The cDNA fragments coding GLP-1 and HSA were amplified by PCR using pMD18T/GLP-1 and pMD18T/HSA as templates, using the following primers:
0 . Because primers P2 and P3 had complementary linker (GGGGS) sequences, the GLP-1/HSA fusion gene was amplified by PCR using a mix of the two PCR products above as template, with P1 and P4 as primers. The PCR product was digested with EcoR I and Not I and ligated into the same enzyme digested vector pPIC9K, resulting in the recombinant vector pPIC9K/GLP-1/HSA (Fig. 1) . The recombinant vector was transformed into E. coli DH5 for amplification and DNA sequence analysis.
Recombinant vector pPIC9K/GLP-1/HSA was linearized by Sal I and introduced into P. pastoris GS115 (his4) by electroporation. Transformants were initially screened for their viability in the absence of histidine. The positive recombinants were identified by PCR using primers P1 and P4, and were analyzed with a 0.8% agarose gel. Further, the positive recombinants were screened in a YPD plate (1% yeast extract, 2% peptone, 2% glucose, 1.5% agar) with a G418 concentration of 0.5 to 5.0 mg/ml, and incubated in 28 C for 7 d.
Expression of GLP-1/HSA fusion protein. The recombinants were inoculated in 25 ml of BMGY medium (100 mM potassium phosphate buffer, pH 6.0, 1% yeast extract, 2% peptone, 4 Â 10 À5 % biotin, 1% v/v glycerol) and the culture was incubated at 30 C overnight. The cells were then collected by centrifugation at 5,000 g for 10 min and resuspended in 100 ml BMMY medium (BMGY with 0.5% methanol instead of 1% glycerol). The cultures were incubated for 60 h at 30 C with constant shaking, and 100% methanol was added to a final concentration of 0.5% every 12 h to maintain induction. The supernatant was harvested by centrifugation at 5,000 g for 10 min and then stored at 4 C until used.
SDS-PAGE and western blot. Twelve percent polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) was performed by the Laemmli method, 23) and the gel was fixed and silver stained, as described previously. 24) After separation by SDS-PAGE, proteins were transferred onto a nitrocellulose membrane following the procedure developed by Towbin et al. 25) The membrane was blocked with 5% dried skim milk in PBS (0.02 M sodium phosphate buffer, pH 7.4, 0.15 M NaCl) overnight at 4 C and incubated with mouse anti-GLP-1 (7-37) IgG (1:10,000) for 2 h at 37 C. The membrane was washed six times with PBST (PBS containing 0.1% Tween 20) and incubated with HRP-labeled goat anti-mouse IgG (1:2,000) for 1.5 h at 37 C. Finally, the membrane was washed again with PBST and developed with diaminobenzidine (DAB) as the substrate.
Quantification of GLP-1/HSA by competitive ELISA. The quantity of GLP-1/HSA was determinated by measuring the amount of HSA by competitive ELISA. Rabbit anti-HSA antibodies were prepared as described by Tian et al. 26) Ninety six well plates were coated with 100 ml of 2 mg/ml standard HSA at 37 C for 2 h, and then blocked overnight at 4 C with 200 ml 5% normal goat serum. After two washes with PBS, the plates were incubated with 100 ml of serially diluted standard HSA or samples, together with 100 ml rabbit anti-HSA IgG (1:100,000) for 3 h at 37 C. After six washes with PBST, the plates were incubated at 37 C for 1 h with 100 ml HRP-labeled goat anti-rabbit IgG (1:2,000). The plates were finally washed again, and 100 ml of Ophenylenediamine (OPD) substrate solution was added to each well. The reaction was stopped after 5 min by the addition of 1 M H 2 SO 4 , and quantification was based on the absorbance at 490 nm. The content of GLP-1/HSA was calculated according to the mass rate of HSA to GLP-1/HSA (1:1.06).
Preparation of immunomagnetic cellulose microspheres (IMCMS). Magnetic cellulose microsphere (MCMS) coupling with anti-HSA antibodies was preformed according to our previous report. 27) Briefly, 10 ml MCMS were prepared by a suspension embedding procedure. For immobilization of anti-HSA antibodies, MCMSs were first activated by treatment with an equal volume of epichlorohydrin, followed by reaction with ammonia hydroxide and glutaraldehyde (GA) in turn. GA-activated MCMS were washed and incubated with anti-HSA antibodies (in 0.01 M Na 2 CO 3 -NaHCO 3 buffer, pH 9.6) overnight. After coupling, IMCMSs were blocked with 1 M glycine and induced to undergo an Amadori rearrangement, forming a stable linkage, with sodium borohydride. After they were washed thoroughly with PBS, IMCMSs were ready for use.
IMS of GLP-1/HAS. Supernatant of the fermentation broth containing GLP-1/HSA was added to a syringe containing the IMCMSs and incubated on a shaker overnight at 4 C. After installation of the syringe into a magnetic separator, the washing procedure could be performed simply by importing and removing the magnetic plate from the separator. Dissociation of GLP-1/HSA was facilitated with 0.1 M of Gly-HCl buffer (pH 2.5), and the eluate was dialyzed, condensed, and stored at 4 C. Finally, IMCMSs were washed with PBS containing 1‰ sodium hydrazoate, and stored at 4 C for reuse. All the procedures were carried out with flow-through magnetic separator designed and made in our laboratory.
High-performance liquid chromatography (HPLC) analysis. Purity analysis of GLP-1/HSA was carried out by HPLC with a Shimadzu Model LC-10ATVP HPLC apparatus (Shimadzu, Kyoto, Japan) using a SPD-10AV UV detector, processing the samples on a TSK-GEL G2000SWXL column (30 cm Â 7:8 mm i.d.) (Tosoh, Tokyo). The column temperature was maintained at 25 C. Detection was performed by measuring the UV absorbance at 280 nm, and purity was calculated by analyzing the peak area of GLP-1/HSA. The mobile phase was 0.15 M NaCl and 0.02 M sodium phosphate (pH 7.0), with a flow rate of 0.8 ml/min.
Mass spectrometry. The samples were prepared by a 1:1 dilution with the UV-absorbing matrix sinapinic acid (SA), and analyzed on a Reflex-III matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) instrument (Bruker-Franzen Analytik, Bremen, Germany). The instrument control and data processing were conducted with software supplied by Bruker-Franzen.
Glucose tolerance tests. Oral glucose tolerance tests were performed after the KM mice fasted overnight (16-18 h). 28) Glucose (1.5 mg/g body wt) was administered orally through a gavage tube. Blood samples were drawn from the tail vein at different times after glucose administration, and blood glucose levels were measured by the glucose oxidase method with a glucose kit. All data were expressed as mean AE SD. Statistical significance was calculated with SPSS windows version 10 (SPSS, Chicago, IL) by Student's t-test. Significance was set at P < 0:05.
Determination of plasma total GLP-1/HSA level. Two groups of male KM mice were intraperitoneally administered saline and GLP-1/HSA (0.1 mmol/kg), respectively. Blood samples were drawn from the tail vein at predetermined time points, and the concentration of GLP-1/HSA in the plasma was analyzed by Sandwich-ELSA. Briefly 96-well plates were coated with 10 mg/ml rabbit anti-HSA IgG at 37 C for 2 h and then blocked overnight at 4 C. After two washes with PBS, the plates were incubated with serially diluted GLP-1/ HSA or blood samples for 1 h at 37 C. After six washes with PBST, the plates were incubated at 37 C for 1 h with mouse anti-GLP-1(7-37) IgG (1:10,000). The plates were washed again and incubated with HRPlabeled goat anti-mouse IgG (1:2,000) for 1 h at 37 C. Development was performed by the addition of OPD, and was read at 490 nm. The total concentration of GLP-1/HSA in the plasma was calculated according to the standard curve.
Results

Construction of expression vector and screening of recombinant P. pastoris stain
The GLP-1/HSA fusion gene, inserted into the pPIC9K plasmid, was confirmed by DNA sequencing. The result showed that the inserted sequence accorded with the designed sequence and was in the same frame as the signal sequence. The linearized pPIC9K/GLP-1/ HSA was transformed into P. pastoris GS115 (his4) and integrated into the genome DNA by homologous recombination. The transformants were cultured on media without histidine, and positive colonies were subjected to PCR analysis. The PCR products exhibited GLP-1/HSA fusion gene bands of 1.9 kb. These results indicated that the target fragment was integrated into the genome of GS115. The positive recombinants were further selected on a YPD plate with G418 for multicopy integration. The result showed that the highest resistance to G418 was 3.0 mg/ml, and 10 clones were chosen for expression analysis.
Expression of GLP-1/HSA fusion protein Small-scale expression was carried out with 10 selected G418 resistant clones, and the expression quantity of GLP-1/HSA was measured by ELISA. The result showed that the highest expression quantity was 58.5 mg/l. Furthermore, the supernatant of the broth was analyzed by SDS-PAGE and western blot. As shown in Fig. 2 , compared with the negative control stain, an obvious band about 70 kD of GLP-1/HSA was visualized in the supernatant of the broth of recombinant stain GS115-pPIC9K/GLP-1/HSA, and then the GLP-1 antigenicity of fusion protein was identified by western blot with anti-GLP-1 antibody. These results indicated that GLP-1/HSA was successfully expressed and secreted into the broth.
Determination of IMS conditions
A comparative study of adsorbed amounts of GLP-1/ HSA at different supernatant quantities from 0.5 to 4 ml using 1 ml IMCMS is shown in Fig. 3 . When the supernatant was less than 2 ml, the adsorption of GLP-1/ HSA was directly raised by raising the amount of supernatant. However, the adsorbed amount was not raised any longer when the supernatant exceeded 2 ml. The maximum amount of GLP-1/HSA adsorbed was 0.11 mg at 2 ml of supernatant (corresponding total protein of 9 mg) for 1 ml of IMCMSs.
Further, the process of IMS was confirmed by SDS-PAGE analysis of every fraction of IMS. As showed in Fig. 4 , after loading of the supernatant of broth onto the IMCMSs, some proteins other than GLP-1/HSA were also adsorbed onto the magnetic carriers due to nonspecific binding, which was overcome by washing with PBS three times. The elution was carried out with 0.1 M Gly-HCl buffer (pH 2.5) three times at an interval of 1 h. Almost all of the bound GLP-1/HSA was eluted in the first fraction, and little trace of GLP-1/HSA was identified from the second and third elutions. Hence subsequent IMS experiments were carried out on the elution behavior of 0.1 M Gly-HCl buffer (pH 2.5) for 1 h. The high purity of GLP-1/HSA, as evidenced by a single, strong band in the first elution, confirmed the optimum and applicable operation conditions.
Purification and characterization of GLP-1/HSA Purification of GLP-1/HSA from the supernatant of the fermentation broth after the determination of IMS conditions was carried out with 10 ml IMCMSs three times. The results shown in Table 1 suggested that recovery of the GLP-1/HSA by IMS reached 90.6%, and that purity was enhanced 72.8 times. Further purity analysis of GLP-1/HSA by HPLC (Fig. 5A) showed an overall purity of 93.9%. The molecular mass of purified GLP-1/HSA analyzed by MALDI-TOF-MS showed a single component of 70,169.2 Da (Fig. 5B) , the predicted molecular weight of GLP-1/HSA.
In vivo activity evaluation of GLP-1/HSA To ascertain whether GLP-1/HSA would activate GLP-1 receptor-dependent processes in vivo, we performed oral glucose tolerance tests on KM mice. GLP-1/HSA, at doses of 0.01, 0.1, and 1 mmol/kg, significantly reduced glycemic excursion after intraperitoneal administration to KM mice (P < 0:05, P < 0:05, and P < 0:01 respectively; Fig. 6 ). Importantly, at 0.1 mmol/ kg, the glucose-lowering effect of GLP-1/HSA was still evident up to 4 h after administration. In contrast, GLP-1 at 0.1 mmol/kg had not lowered glucose levels 1 h after administration (Fig. 7) .
Plasma total GLP-1/HSA levels were evaluated following intraperitoneal administration in KM mice. As shown in Fig. 8 , the total concentration of GLP-1/ HSA in the plasma reached 1.4 mg/ml 1 h after administration, and later significantly higher GLP-1/HSA levels were maintained for 12 h as compared to the control group.
Discussion
Pichia pastoris is a powerful, inexpensive heterologous expression system for the production of functionally active recombinant proteins. This system combines the advantages of high expression levels, easy scale-up, inexpensive growth media, and a capacity to perform most of the post-translational modifications characteristic of higher eukaryotes. 29) In addition, the secretor type P. pastoris expression system can secret target protein into broth, which facilitates the following purification process. In this study, we expressed the fusion protein GLP-1/HSA using the secretor type P. pastoris expression system, and the expression quantity reached 58.5 mg/l in small-scale incubation.
Since the introduction of encapsulated magnetic materials in the 1970s, there has been a broad variety of MMSs applied to IMS of target proteins. 30, 31) As an easily separable and reproducible support material, MMSs offer exciting new opportunities to develop effective purification systems by virtue of their simple One-Step Purification of Fusion GLP-1/HSA Expressed in P. pastoris by IMSand convenient handling. Among the various available MMS materials, MCMSs exhibit good characteristics as biological materials with highly favorable biocompatibility and preferred efficiency. 32) Abundant free hydroxyl groups appearing on MCMSs can easily be activated and coupled with adequate ligands for long-lasting and repetitive use. At present, MCMSs are widely applied in the immobilization of enzymes, medical immunoassay, and affinity purification. 33, 34) In previous studies, we successfully purified interferon -2b (IFN-2b) from crude cell lysate using MCMSs coupled with anti-IFN2b antibodies.
In this study, MCMSs coupled with anti-HSA antibodies were prepared and applied to the purification of GLP-1/HSA from supernatant of broth. The IMCMSs were reused for the purification of GLP-1/HSA more than 10 times, without showing any performance decrease during IMS (data not shown). Current methods for the purification of recombinant proteins, including gel filtration chromatography, ionexchange chromatography, hydrophobic chromatography, and affinity chromatography, either provide high purity but low recovery, or involve troublesome procedures, but, IMS produced high purity target proteins by one-step purification, and is regarded as an efficient and convenient alternative to current purification methods.
Furthermore, analysis of in vivo activity revealed that GLP-1/HSA reduced blood glucose levels after intraperitoneal administration to KM mice in a dose-dependent manner. Although native GLP-1 immediately showed a significant glucose-lowering effect after administration, the effect disappeared 1 h after administration. Compared to native GLP-1, GLP-1/HSA significantly reduced blood glucose levels in KM mice 4 h after administration. Although conjugation of HSA with GLP-1 hindered renal clearance of GLP-1, the degradation of DPP-IV still existed. After administration, perhaps there are two types of GLP-1/HSA in the plasma, intact GLP-1(7-37)/HSA and degraded GLP-1(9-37)/HSA, and only the intact GLP-1(7-37)/HSA has bioactivity. In the pharmacokinetic analysis test, mouse anti-GLP-1(7-37) polyclonal antibody was used, so that the GLP-1/HSA concentration in the plasma was the total concentration of the two types GLP-1/HSA intermixed. Although higher total GLP-1/HSA levels were maintained for 12 h in the plasma, the GLP-1(7-37)/HSA with bioactivity had been degraded, possibly by DPP-IV. Therefore, the glucose-lowering effect of GLP-1/HSA only lasted 4 h. In future research, we will study further the metabolic process of GLP-1/HSA and attempt to develop a fusion protein of the DPP-IVresistant GLP-1 analog with HSA in order to further prolong the action time in vivo.
